Erratum: Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer
Erratum to: Transl Androl Urol 2022;11:643-58.
In the article entitled “Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer” (1), three pairs of images across Figure 7F and Figure 7H, selected to represent transwell assays that detected the invasion of C4-2 and C4-2b cells, were erroneously arranged.
Figure 7F and 7H of the original article:
The correct version of Figure 7 is shown below.
The authors regretted the error and confirmed that this error did not significantly affect either the results or the conclusions of the paper.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Ye C, Chen YG, Qin SF, et al. Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer. Transl Androl Urol 2022;11:643-58. [Crossref] [PubMed]
